Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial

BACKGROUND: Respiratory syncytial virus (RSV) is responsible for most respiratory tract infections and hospitalizations in infants and represents a significant economic burden for public health. The development of a safe, effective, and affordable vaccine is a priority for the WHO. METHODS: We condu...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:EClinicalMedicine
Main Authors: Abarca, Katia, Rey-Jurado, Emma, Muñoz-Durango, Natalia, Vázquez, Yaneisi, Soto, Jorge A., Gálvez, Nicolás M.S., Valdés-Ferrada, Javier, Iturriaga, Carolina, Urzúa, Marcela, Borzutzky, Arturo, Cerda, Jaime, Villarroel, Luis, Madrid, Victoria, González, Pablo A., González-Aramundiz, José V., Bueno, Susan M., Kalergis, Alexis M.
Formato: Artigo
Idioma:Inglês
Publicado: Elsevier 2020
Assuntos:
Research paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7548429/
https://ncbi.nlm.nih.gov/pubmed/33073219
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2020.100517
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares